Related Experiment Video

Updated: Jun 19, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Post-menopausal hormone therapy and cardiovascular events: a new paradigm based on pharmacogenetics?

Glen E Cooke1

  • 1The Ohio State University, 235 Davis Heart and Lung Research Institute, 473 W. 12th Ave, Columbus, OH 43210-1252, USA. glen.cooke@osumc.edu

Future Cardiology
|October 7, 2009
PubMed

Insights

Hormone therapy (HT) does not reduce coronary heart disease (CHD) risk in postmenopausal women. Genetic variations in platelet glycoproteins may guide future HT decisions for personalized cardiovascular risk management.

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Endocrinology

Background:

  • Postmenopausal women face increased coronary heart disease (CHD) risk.
  • Hormone therapy (HT) was hypothesized to mitigate this risk.
  • However, clinical trials show mixed results, with some indicating no benefit or even increased cardiovascular events.

Purpose of the Study:

  • To investigate the role of platelet glycoprotein single-nucleotide polymorphisms (SNPs) in CHD risk.
  • To explore the potential of genetic profiling for personalizing HT efficacy and safety.
  • To identify patient subgroups who may benefit from or be harmed by HT for CHD prevention.

Main Methods:

  • Review of large randomized clinical trials on HT and cardiovascular events.
  • Analysis of platelet glycoprotein single-nucleotide polymorphisms (SNPs).
  • Exploration of genetic markers for predicting treatment response to HT.

Main Results:

  • Large trials failed to show reduced CHD risk with HT in secondary prevention.
  • Some primary prevention studies indicated an increased risk of cardiovascular events with HT.
  • Platelet glycoprotein SNPs show potential for identifying individual risk and treatment efficacy.

Conclusions:

  • HT is not a universally effective strategy for reducing CHD risk in postmenopausal women.
  • Genotyping for platelet glycoprotein SNPs could enable personalized medicine approaches.
  • Future clinical practice may involve genetic screening to guide HT decisions, optimizing benefits and minimizing harm.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...